Patents by Inventor Nicholas E. Goeders
Nicholas E. Goeders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033258Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: September 29, 2023Publication date: February 1, 2024Applicant: Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventor: Nicholas E. Goeders
-
Publication number: 20220202791Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: August 9, 2021Publication date: June 30, 2022Inventor: Nicholas E. Goeders
-
Patent number: 10702537Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.Type: GrantFiled: June 4, 2018Date of Patent: July 7, 2020Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY and Agricultural and Mechanical CollegeInventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
-
Patent number: 10561668Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.Type: GrantFiled: June 4, 2018Date of Patent: February 18, 2020Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
-
Publication number: 20190224211Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.Type: ApplicationFiled: June 4, 2018Publication date: July 25, 2019Inventors: Nicholas E. GOEDERS, Christopher Dalton SCHMOUTZ
-
Patent number: 10022383Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.Type: GrantFiled: June 7, 2016Date of Patent: July 17, 2018Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
-
Patent number: 9987286Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: GrantFiled: June 11, 2015Date of Patent: June 5, 2018Assignees: EMBERA NEUROTHERAPEUTICS, INC., BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGEInventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Publication number: 20160367565Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.Type: ApplicationFiled: June 7, 2016Publication date: December 22, 2016Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nicholas E. GOEDERS, Christopher Dalton SCHMOUTZ
-
Publication number: 20160346261Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: August 12, 2016Publication date: December 1, 2016Applicant: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical CollegeInventor: Nicholas E. Goeders
-
Patent number: 9415107Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: GrantFiled: November 13, 2006Date of Patent: August 16, 2016Assignee: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical CollegeInventor: Nicholas E. Goeders
-
Publication number: 20160038509Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: ApplicationFiled: June 11, 2015Publication date: February 11, 2016Applicant: EMBERA NEUROTHERAPEUTICS, INC.Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Patent number: 9078886Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: GrantFiled: June 16, 2011Date of Patent: July 14, 2015Assignees: Embera Neurotherapeutics, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Publication number: 20130303523Abstract: The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.Type: ApplicationFiled: June 16, 2011Publication date: November 14, 2013Applicant: EMBERA NEUROTHERAPEUTICS, INC.Inventors: Nicholas E. Goeders, Barbara S. Fox, Glenn Guerin
-
Publication number: 20120208795Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: January 13, 2012Publication date: August 16, 2012Applicant: Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventor: Nicholas E. Goeders
-
Publication number: 20090203669Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.Type: ApplicationFiled: November 13, 2006Publication date: August 13, 2009Inventor: Nicholas E. Goeders
-
Patent number: 5869474Abstract: Ketoconazole is used for treating cocaine addiction. Mammals, including humans, that are chronically addicted to cocaine are treated with ketoconazole to decrease self-administration of the drug.Type: GrantFiled: May 16, 1997Date of Patent: February 9, 1999Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Nicholas E. Goeders